Company record
A clear public starting point.
This page gathers the company’s published description, taxonomy, status, and official link in one place. It does not make claims about private activity or deal terms.
Startup in Sahin’s portfolio

Simulates drug response in human biology using LLMs.
CellType builds AI models that simulate biology so drug developers can predict how compounds affect cells, safety and patients. Its products include CT-Perturb, CT-Tox and CT-Translate.
Source: CellType
Yes, CellType was in Y Combinator's Winter 2026 batch and is based in New York. Its work builds on Cell2Sentence, a method published at ICML 2024 that teaches language models to read single-cell data.
Source: Y Combinator
David van Dijk, a Yale professor, is CellType's co-founder and CEO. He co-developed the Cell2Sentence research behind the company.
Source: Y Combinator
As an angel investor in 231 startups across 14 categories, I look for companies with exceptional founders, large addressable markets, and clear competitive advantages. CellType stood out in the Biotech space.
Company record
This page gathers the company’s published description, taxonomy, status, and official link in one place. It does not make claims about private activity or deal terms.